Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia (THRiL for WM)
|ClinicalTrials.gov Identifier: NCT01779167|
Recruitment Status : Terminated (Slow Accrual)
First Posted : January 30, 2013
Results First Posted : April 7, 2017
Last Update Posted : May 30, 2017
|Condition or disease||Intervention/treatment||Phase|
|Waldenstrom Macroglobulinemia||Drug: Thalidomide Drug: Lenalidomide Drug: Rituximab||Phase 2|
Waldenstrom macroglobulinemia (WM) is an incurable B-cell lymphoproliferative disorder characterized by expansion of malignant B-lymphocytes and excessive production of monoclonal IgM. The survival and proliferation of the neoplastic WM cells is highly dependent on signals from the microenvironment. Thalidomide and lenalidomide are immunomodulatory agents with single agent activity in WM. Their use is limited by significant toxicities, including tumor flare (thalidomide and lenalidomide); sedation, constipation, and neuropathy (thalidomide); and cytopenias (lenalidomide). Alternating doses of thalidomide and lenalidomide may alleviate the toxicities, while preserving efficacy since the agents have non-overlapping toxicities and yet similar hypothesized mechanisms of action. Additionally, starting at a lower dose of lenalidomide than previously studied in WM may allow for improved tolerability. A pilot study of daily alternating therapy in subjects with chronic lymphocytic leukemia demonstrated that the two agents could be combined with non-overlapping toxicity. This phase II study aims to evaluate the efficacy and safety of daily alternating thalidomide and lenalidomide plus rituximab (ThRiL) in subjects with previously treated WM.
Subjects will receive thalidomide 50 mg every other day (i.e., every odd day: days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 & 27 of a 28 day cycle) alternating with lenalidomide on every other day (i.e., every even day: days 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 & 28 of a 28 day cycle), dosed based upon stepwise incremental dosing. Rituximab 375 mg/m2 will be administered on days 1, 8, 15 and 22 starting with Cycle 1 and then again on the same weekly x 4 schedule every 6th cycle thereafter (Cycles 7, 13, 19, etc).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||4 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2 Trial of Daily Alternating Thalidomide and Lenalidomide Plus Rituximab (ThRiL) for Patients With Previously Treated Waldenstrom Macroglobulinemia|
|Study Start Date :||June 2012|
|Actual Primary Completion Date :||October 2013|
|Actual Study Completion Date :||April 2014|
U.S. FDA Resources
Experimental: All Patients
Daily alternating thalidomide and lenalidomide plus rituximab (ThRiL) in patients with previously treated WM
Thalidomide 50 mg (every ODD day of a 28 day cycle: Days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 & 27)Drug: Lenalidomide
Lenalidomide (every EVEN day of a 28 day cycle: Days 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 & 28). Lenalidomide will be initiated at a starting dose of 5 mg.
Other Name: RevlimidDrug: Rituximab
Rituximab 375 mg/m2 IV on Days 1, 8, 15 and 22 (+/- 2 days) and then again on the same weekly x 4 schedule every 6th cycle thereafter (Cycle 7, 13, 19, etc).
Other Name: Rituxan
- Number of Patients Who Demonstrate a Response (Complete, Partial, Minor) to Treatment [ Time Frame: Approximately 24 months ]
Response criteria for subjects with WM is based upon the Consensus Panel Recommendations from the Third International Workshop on Waldenstrom Macroglobulinemia.
Overall response rate (CR + PR + MR) measured at time of best response.
- Number of Adverse Events Experienced With Alternating Thalidomide and Lenalidomide Plus Rituximab for Subjects With Previously Treated Waldenstrom's Macroglobulinemia [ Time Frame: approximately 24 months per patient ]Capture the number of adverse events experienced when combining thalidomide, lenalidomide, and rituximab in patients with previously treated WM
- Survival of Subjects Treated With THRiL for WM. [ Time Frame: approximately 24 months per patient ]Estimate overall survival of patients enrolled on THRiL for WM.
- Rate of Rituximab Related IgM Flare [ Time Frame: Approximately 24 months per patient ]Estimate the rate of rituximab-related IgM flare
- Time to Response [ Time Frame: approximately 24 months ]Measure the time from initiating therapy to demonstrating response in WM.
- Response Duration of Subjects Treated With THRiL for WM [ Time Frame: 24 months ]Measure response duration of patients enrolled on THRiL for WM
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01779167
|United States, New York|
|Weill Cornell Medical College|
|New York, New York, United States, 10065|
|Principal Investigator:||Peter Martin, MD||Weill Medical College of Cornell University|